In last trading session, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) saw 2.44 million shares changing hands with its beta currently measuring 0.95. Company’s recent per share price level of $14.91 trading at -$0.37 or -2.42% at ring of the bell on the day assigns it a market valuation of $2.06B. That closing price of ARWR’s stock is at a discount of -103.96% from its 52-week high price of $30.41 and is indicating a premium of 35.81% from its 52-week low price of $9.57. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.84 million shares which gives us an average trading volume of 1.77 million if we extend that period to 3-months.
For Arrowhead Pharmaceuticals Inc (ARWR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.62. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) trade information
Upright in the red during last session for losing -2.42%, in the last five days ARWR remained trading in the green while hitting it’s week-highest on Tuesday, 05/13/25 when the stock touched $14.91 price level, adding 11.41% to its value on the day. Arrowhead Pharmaceuticals Inc’s shares saw a change of -20.69% in year-to-date performance and have moved 14.17% in past 5-day. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) showed a performance of 20.83% in past 30-days. Number of shares sold short was 13.53 million shares which calculate 6.34 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 26.98 to the stock, which implies a rise of 44.75% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 29.97. It follows that stock’s current price would drop -60.97% in reaching the projected high whereas dropping to the targeted low would mean a loss of -60.97% for stock’s current value.
Arrowhead Pharmaceuticals Inc (ARWR) estimates and forecasts
In 2025, company’s earnings growth rate is likely to be around 103.40% while estimates for its earnings growth in next 5 years are of 9.12%.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s Major holders
Insiders are in possession of 13.02% of company’s total shares while institution are holding 77.13 percent of that, with stock having share float percentage of 88.67%. Investors also watch the number of corporate investors in a company very closely, which is 77.13% institutions for Arrowhead Pharmaceuticals Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ARWR for having 15.68 million shares of worth $407.61 million. And as of 2024-06-30, it was holding 12.6275 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 12.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.8343 of outstanding shares, having a total worth of $317.44 million.
On the other hand, iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 7.85 shares of worth $116.98 million or 5.71% of the total outstanding shares. The later fund manager was in possession of 3.66 shares on Dec 31, 2024 , making its stake of worth around $54.61 million in the company or a holder of 2.67% of company’s stock.
